{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-115245","form_type":"8-K","ticker":"RIGL","cik":"0001034842","company_name":"RIGEL PHARMACEUTICALS INC","filed_at":"2023-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.961339+00:00","generated_at":"2026-06-08T12:58:15.086478+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Rigel Q3 2023: Total revenue $28.1M, net loss narrows to $5.7M; TAVALISSE sales record $24.5M","bullets":["Q3 net loss $5.7M ($0.03/share) vs $19.0M ($0.11/share) in Q3 2022.","Total revenue $28.1M: TAVALISSE $24.5M (+27% YoY), REZLIDHIA $2.7M, collaboration $1.0M.","Cash and short-term investments $62.4M at Sep 30, 2023 vs $58.2M at Dec 31, 2022.","Phase 1b R289 (IRAK1/4 inhibitor) in LR-MDS enrolling third cohort; preliminary data expected mid-2024.","NECTAR trial fostamatinib arm ceased enrollment per DSMB recommendation; no safety concerns identified."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-115245","json":"https://secwatch.observer/filing/0001104659-23-115245.json","markdown":"https://secwatch.observer/filing/0001104659-23-115245.md","text":"https://secwatch.observer/filing/0001104659-23-115245.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1034842/000110465923115245/0001104659-23-115245-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1034842/000110465923115245/tm2329984d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T12:58:15.086478+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"68c96a1bd39b51a0cc670d00a4ccf00741b7c143","claim":"RIGEL PHARMACEUTICALS INC reported third quarter ended September 30, 2023 results: revenue $28.1 million, net income net loss of $5.7 million, EPS $0.03 per basic and diluted share.","evidence_excerpt":"2 tm2329984d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Rigel Reports Third Quarter 2023 Financial Results and Provides Business Update · Third quarter 2023 Total Revenue of $28.1 million which includes record TAVALISSE ® net product sales of $24.5 million and REZLIDHIA ® net product sales of $2.7 million · New data on olutasidenib in mIDH1 relapsed or","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1034842/000110465923115245/0001104659-23-115245-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Revenue","value":"$28.1 million"},{"label":"Net income","value":"net loss of $5.7 million"},{"label":"EPS","value":"$0.03 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"ab44f5917db95ff1ee956880ad7df8c0dcdd5488","claim":"RIGEL PHARMACEUTICALS INC reported nine months ended September 30, 2023 results: revenue $81.1 million, net income net loss of $25.8 million, EPS $0.15 per basic and diluted share.","evidence_excerpt":"compared to a net loss of $60.0 million, or $0.35 per basic and diluted share, for the same period of 2022. For the nine months ended September 30, 2023, total revenues were $81.1 million, consisting of $68.1 million in TAVALISSE net product sales, $6.7 million in REZLIDHIA net product sales, $5.3 million in contract revenues from collaborations, and $1.0 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1034842/000110465923115245/0001104659-23-115245-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"nine months ended September 30, 2023"},{"label":"Revenue","value":"$81.1 million"},{"label":"Net income","value":"net loss of $25.8 million"},{"label":"EPS","value":"$0.15 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}